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Abstract 
 
The intestine is a major interface between the human body and the 
environment, and harbours a dense population of immune cells, as well as a 
diverse microbial ecosystem. The immune system of the infant develops in 
tight interaction with the intestinal microbiota, and the early-life microbiota 
succession is considered important for immune maturation. Many common 
practices, such as birth by Caesarean section, antibiotics, and lack of 
breastfeeding, influence the development of the infant’s microbiota. The 
altered early microbiome may have long-term effects on the later health of the 
child.  
This thesis characterises the development of the intestinal microbiota 
in healthy children. The influence of four common factors potentially 
modulating the microbiota – prenatal stress, breastfeeding duration, 
antibiotic use, and probiotic use – were investigated, as well as the association 
between early-life microbiota composition and the development of BMI. In 
addition, the microbiota in healthy children was contrasted with that that of 
children with IBD, characterising the association between treatment response 
and microbiota.  
DNA-based methods were used for microbiota profiling from frozen 
faecal samples. The bacterial composition was studied using two methods, a 
phylogenetic microarray, HITChip, as well as 454-pyrosequencing of the 16S 
rRNA gene amplicons. In addition, real-time qPCR was conducted to measure 
bile-salt hydrolase genes and antibiotic resistance genes. Bacteria were 
cultured anaerobically from the faecal samples for antibiotic susceptibility 
testing.  
The results showed that the microbiota in childhood are sensitive to 
modulating factors, and are predictive of later-life health. Maternal stress 
during pregnancy was associated with altered microbiota development over 
the first months of life. Short duration of breastfeeding was associated with 
fast microbiota maturation, high BMI, and frequent antibiotic use in pre-
school age. The results indicate that some of the benefits of breastfeeding are 
microbiota-dependent. Antibiotic use emerged as a central regulator of the 
microbiome, with potential effects on the metabolic development of the child. 
LGG supplementation prevented some of the penicillin-associated changes, 
but failed to prevent the macrolide-associated loss of bifidobacteria. In IBD 
patients, the microbiota composition varied along a gradient of intestinal 
inflammation. High microbiota similarity to healthy controls predicted 
positive response to anti-TNF-α treatment in IBD patients.  
This work suggests that maternal wellbeing is the first step towards a 
healthy microbiota in the child. Promoting a natural microbiota development 
in childhood by breastfeeding, avoiding unnecessary antibiotics, careful 
selection of the antibiotic when it is needed, and possibly the use of specific 
probiotic strains, may have long-term health benefits, particularly in terms of 
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weight development and immune health. Furthermore, healthy children 
treated with antibiotics showed considerable microbiota similarities to IBD 
patients, suggesting that antibiotic courses may drive the microbiota towards 
an IBD-like state. Stratification of paediatric IBD patients based on the 
microbiota may enable tailored treatment and improved treatment responses. 
Introduction 
 
The intestine is a major interface between the human body and the 
environment, and harbours a dense population of immune cells and a diverse 
microbial ecosystem, consisting largely of bacteria but also of archaea and 
viruses (Qin et al. 2010, Lozupone et al. 2012). The intestinal microbiota have 
co-evolved with the host species (Xu et al. 2007, Ley et al. 2008). In this 
process the gut microbes have taken on many metabolic functions, which the 
host cells cannot perform (Qin et al. 2010, Sekirov et al. 2010). The human 
intestinal microbiota are composed mostly of bacteria belonging to four 
phyla: the Gram-positive Firmicutes and Actinobacteria, and the Gram-
negative Bacteroidetes and Proteobacteria (Costello et al. 2009, Human 
Microbiome Project Consortium 2012, Rajilić-Stojanović and de Vos 2014). In 
addition, several other phyla are present at low levels. At finer taxonomic 
levels, there is substantial variation between individuals, and each adult has a 
unique and stable microbiota composition (Rajilić-Stojanović et al. 2013). 
Most intestinal microbes have not yet been cultured, although over 1000 
species have now been described (Rajilić-Stojanović and de Vos 2014). 
Molecular, culture-independent approaches are therefore essential to 
comprehensively characterise the microbiota. 
Microbial colonization of the infant may begin in utero, as bacterial 
DNA can be detected in the placenta (Aagaard et al. 2014) and in the 
meconium even in healthy pregnancies (Gosalbes et al. 2013, Ardissone et al. 
2014). However, a massive colonization begins at birth, during and after 
which the infant is exposed to a rich diversity of parental and environmental 
bacteria. During the first weeks and months of life, there is large, inter- and 
intra-individual variation in the microbiota composition (Palmer et al. 2007, 
Eggesbo et al. 2011, Valles et al. 2012, Sharon et al. 2013). The causes of this 
variation are not fully understood. However, despite the vast diversity of 
environmental bacteria, to which the neonate is exposed, the intestinal 
colonizers are normally exclusively human-associated bacteria, and common 
patterns can be recognized in the process, even across cultures (Scholtens et 
al. 2012, Yatsunenko et al. 2012). It is becoming increasingly recognized that 
maternal vertical transmission of microbes is an important and finely 
orchestrated process, with evolutionary implications comparable to the 
inheritance of genetic material (Funkhouser and Bordenstein 2013). The 
immune system of the infant develops in tight interaction with the intestinal 
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microbiota, and the early-life microbiota succession is considered highly 
important for proper immune maturation (Martin et al. 2010). 
The intestinal microbiota interact closely with the host’s immune 
system and regulate metabolism (Hooper et al. 2012). The intestinal microbes 
play an essential role e.g. in the metabolism of bile acids and cholesterol, 
production of energy-rich short chain fatty acids from undigested fibre, and in 
the functioning of the intestinal epithelial and immune cell populations 
(Nicholson et al. 2012, Tremaroli and Bäckhed 2012). The symbiotic 
microbial communities living within the human host have been suggested to 
protect against allergic diseases and aberrant immune responses (Beyan et al. 
2012, Hoermannsperger et al. 2012). Furthermore, the intestinal microbes 
protect the host from bacterial and viral infections by stimulating the immune 
system (Kinnebrew et al. 2012), and the intestinal barrier (Wlodarska et al. 
2011) and out-competing pathogens (Croswell et al. 2009, Endt et al. 2010). 
The individual composition of the microbiota is linked to the health of the 
host: altered composition or function has been associated with intestinal and 
systemic inflammatory, autoimmune and metabolic diseases (Festi et al. 2011, 
Iebba et al. 2011, Burcelin et al. 2012, Greenblum et al. 2012). Rather than 
being attributed to a single pathogenic bacterium, many disease states are 
associated with some degree of alteration in the overall composition and 
functioning of the microbiota as an ecosystem.  
Literature review 
Human microbiomes 
 
The abundance of bacteria and the community composition vary widely along 
the intestinal tract due to changes in conditions such as pH, oxygen level, 
nutrient content, and peristalsis  (Stearns et al. 2011). The mouth has a 
diverse microbiota consisting of both aerobic and anaerobic organisms, with 
different communities found in different habitats (Dewhirst et al. 2010, 
Stearns et al. 2011). All of the phyla inhabiting the intestine are also found in 
the mouth, and the mouth is considered a microbial gateway to other body 
sites, including in the intestine (Dewhirst et al. 2010). In the stomach a 
surprisingly rich ensemble of bacteria are found (Bik et al. 2006, Stearns et 
al. 2011); whether they are alive and resident in the stomach is questionable.  
In the intestine, the abundance and diversity of the microbiota increase 
toward the colon (Stearns et al. 2011). The small intestine is an unstable 
environment and the microbiota composition fluctuates within daily time 
scales (Booijink et al. 2010, Zoetendal et al. 2012). There is a rich, but 
pulsatile supply of various types of nutrients that have not yet been absorbed 
by the host, including simple sugars, fatty acids and amino acids.  The 
arriving food is mixed with acids and oxygen, and the host secretes bile and 
digestive enzymes. Furthermore, the transit in the small intestine is much 
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faster than in the colon. Coping with these conditions is necessary for survival 
especially in the proximal small intestine. Microbes with an opportunistic life-
style and fast intrinsic growth rate, able to rapidly utilize available substrates 
(Zoetendal et al. 2012), the so-called r-selected species, thrive in this 
environment. The most abundant genera are Streptococcus, Veillonella, 
Prevotella and various Proteobacteria (Ou et al. 2009, Cheng et al. 2013, 
Wacklin et al. 2013, Dlugosz et al. 2015). The microbes compete for nutrients 
with the host, and furthermore, the small intestine is the site where nutrient 
absorption occurs; the host must balance between compartmentalising the 
bacteria strictly into the intestine while simultaneously efficiently taking up 
nutrients into circulation. The host therefore has to limit the growth of 
microbes in the small intestine. The ileocaecal valve limits the translocation of 
microbes from the colon where the microbial density is much higher than in 
the upper intestinal tract, and the host secretes IgA and antibacterial 
compounds to control the microbes and to keep their density low (Salzman et 
al. 2007). 
Toward the distal ileum, the transit slows down, the level of anoxia 
increases, the pH increases (Evans et al. 1988), and the conditions begin 
gradually to resemble those in the colon. In a healthy state, the human colon 
is a very stable environment, with fairly continuous input of complex 
polysaccharides to be utilized for energy, as well as close-to-neutral pH, and 
very low levels of oxygen. Thus the dominant species are adapted to such 
conditions, i.e., can be expected to be so called K-selected species that are 
highly specialized and competitively dominant in their preferred, stable 
environment. The host has adapted to coexisting with these microbes, whose 
metabolic products feed the colonocytes and maintain intestinal health. The 
dominant components of the colonic microbiota are to be considered 
mutualistic symbionts, depending on the host for survival and providing the 
host with various benefits. The dominant members in adult humans are those 
belonging to Firmicutes, mainly Clostridium clusters IV and XIVa, and 
Bacteroidetes (Costello et al. 2009, Human Microbiome Project Consortium 
2012, Rajilić-Stojanović and de Vos 2014).  
In addition to the digestive tract, all external surfaces of the human 
body, including the skin and the urogenital tract are inhabited by their own 
microbiomes (Human Microbiome Project Consortium 2012). Skin surfaces 
are often dominated by Propionibacterium, Corynebacterium, staphylococci 
or Proteobacteria, with wide variations in community composition between 
different types of skin habitats (Grice et al. 2009). The vaginal microbiota are 
particularly important for early colonisation and transmission of microbes 
from mother to child, and therefore likely to have played a major role in the 
evolution of the human-microbe symbiosis. The vaginal microbiota are 
usually dominated by one of three Lactobacillus species: L. iners, L. 
crispatus, L. gasseri, (in a few cases L. jensenii) or alternatively characterised 
by low abundance of lactobacilli and high diversity. The latter composition is 
associated with high pH and Nugent scores, indicating bacterial vaginosis. 
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The dominant organisms and their metabolism have important effects on the 
vaginal immune functions and the mucosal barrier, and therefore affect e.g. 
resistance to pathogens (Doerflinger et al. 2014). 
 
Factors influencing the intestinal microbiota 
 
At the level of genera and species, the composition of the microbiota shows 
considerable inter-individual variation. Each individual has a unique 
microbial fingerprint, which tends to be stable over time and resilient, but not 
always resistant, to perturbations (Martinez et al. 2013, David et al. 2014a). 
The microbiota composition is influenced by host genetics and the 
environment (Benson et al. 2010, Kashyap et al. 2013, Carmody et al. 2015). 
In humans, genetic loci influencing fucosylation of secreted glycans (FUT2), 
and innate immunity (MEFV) have been shown to influence the composition 
and functioning of the microbiota, with health implications (Khachatryan et 
al. 2008, Tong et al. 2014, Wacklin et al. 2014). However, the similarity in 
microbial profiles between monozygotic twins has not consistently been 
found to be greater than that of dizygotic twins (Zoetendal et al. 2001, 
Stewart et al. 2005, Turnbaugh et al. 2009, Tims et al. 2013). Spouses tend to 
resemble each other in their microbiota profiles more than other people and 
more than their children (Song et al. 2013), suggesting that shared 
environment has an important role. The microbiota are capable of adaptation 
to different situations, and respond rapidly to changes in diet (David et al. 
2014b). Diet influences the microbiota by providing substrates for microbial 
fermentation, inducing host secretions, and possibly also directly by 
providing incoming bacteria (Salonen and de Vos 2014, Zoetendal and de Vos 
2014). Some food-borne bacteria remain viable and metabolically active in the 
gut (David et al. 2014b). In addition to diet, the microbiota composition 
varies according to e.g., country, health status, and age of the individual 
(Yatsunenko et al. 2012). Hunter-gatherer communities harbour a much 
greater intestinal microbial diversity and a different composition than 
humans living in modern environments (Schnorr et al. 2014, Clemente et al. 
2015), suggesting that modernization has simplified the human-associated 
microbiota.  
 
Functions of the intestinal microbiota 
 
The intestinal microbiota function essentially as an organ, performing tasks 
that the host cells do not have the capacity for. Microbes modify the intestinal 
environment to suit their own requirements, e.g. by altering the pH, breaking 
down and metabolizing bile acids, producing bacteriocins and stimulating the 
immune system to inhibit the growth of competing bacteria. The human host 
has evolved to depend on many of these essentially selfish bacterial functions. 
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Many symbiotic microorganisms protect the host from the invasion of 
intestinal pathogens, a phenomenon called colonisation resistance (Buffie and 
Pamer 2013). Lactic acid bacteria are particularly well-studied examples of 
improved colonisation resistance and several mechanisms have been 
elucidated: they produce lactate which decreases the intestinal pH below the 
optimum for many Gram-negative pathogens (Fernandez et al. 2003), they 
produce antibacterial compounds (Cintas et al. 2001), compete for binding 
sites (Fernandez et al. 2003), and interact with the immune system, 
strengthening immune responses to pathogens (Wells 2011).  
The intestinal microbial communities have an essential role in the 
digestion of food: it has been estimated that up to 10% of a person’s daily 
calories on a Western diet come from microbial fermentation (McNeil 1984). 
The dominant members of the colonic microbiota are specialized degraders of 
complex polysaccharides, such as dietary fibres and resistant starch, releasing 
short-chain fatty acids (SCFA) as a result of polysaccharide degradation. 
Butyrate, acetate, and propionate are the most abundantly produced SCFAs 
(Macfarlane and Macfarlane 2003). Butyrate is produced by several species 
belonging to the Firmicutes, especially the Clostridium clusters IV and XIVa, 
propionate by Bacteroidetes and Clostridium cluster IX, and acetate by 
various bacteria (Louis et al. 2007). Methanogens are the only abundant 
archaea found in the intestinal tract and convert hydrogen and carbon dioxide 
into methane. The intestinal pH, which depends on diet, has a strong 
influence on the composition and activity of the microbiota: mildly acidic pH 
favours butyrate-producing Firmicutes, and neutral pH favours propionate-
producing Bacteroides (Walker et al. 2005, Duncan et al. 2009). Bacteria-
derived butyrate provides energy for colonocytes, helps them cope with 
hypoxia, improves the intestinal barrier, and has anti-inflammatory effects 
(Singh et al. 2014, Zheng et al. 2015). Propionate and acetate are transported 
to the liver and used for gluconeogenesis and cholesterol synthesis, 
respectively (Wolever et al. 1991). In addition to fermenting non-digestible 
polysaccharides, certain bacterial species are specialized in host-glycan 
utilization. In early life these species degrade oligosaccharides in breast milk 
(Ward et al. 2006, Marcobal et al. 2011), and in later life the abundant 
mucus-derived glycans. Species belonging to the genera Akkermansia, 
Bifidobacterium, Bacteroides and Ruminococcus are able to utilize mucin 
and are thought to represent key species in the intestinal mucosa, performing 
the first step in mucus degradation and thus unlocking an abundant energy 
source in the gut (Hoskins et al. 1985, Derrien et al. 2004). 
Bile acid metabolism is one the key functions performed by the 
intestinal bacteria, with strong effects on host energy metabolism.  The 
mammalian host produces primary bile acids, conjugated to taurine, or more 
commonly in adult humans, to glycine. Bacterial bile-salt hydrolases de-
conjugate the bile acids, rendering them susceptible for further bacterial 
modification into secondary and tertiary forms (Ridlon et al. 2006). Primary 
bile acids are highly toxic to bacteria, and the modifications have been shown 
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to increase bacterial survival in the presence of bile (Jones et al. 2008). Bile 
salt hydrolases are enriched in the human intestinal microbiota (Jones et al. 
2008), indicating that they confer a selective advantage in the intestinal 
environment. Modified bile acids have been implicated in colorectal cancer, 
but they also function as metabolic regulators by activating several key 
receptors with strong effects on the host’s energy metabolism, such as FXR-α 
and TGR5 (Fiorucci et al. 2009). Bile-salt hydrolase activity of the microbiota 
has been shown to reduce host weigh gain, insulin resistance and blood 
cholesterol, via FXR-α and TGR5 signalling (Smet et al. 1998, Joyce et al. 
2014). Microbial activity in the intestine thus has the potential to regulate 
host energy metabolism via extraction of energy from non-digestible 
compounds and via controlling energy expenditure and storage. SCFAs, 
particularly butyrate, regulate satiety and energy expenditure via gut 
hormones (Lin et al. 2012) and may be involved in the epigenetic 
programming of metabolism-regulating genes (Remely et al. 2014).  
The intestinal microbes are not only beneficial but produce also 
compounds with harmful effects on the host. The microbiota include several 
pathobionts, species with the potential to negatively influence the host, most 
notably by inducing inflammation and even infections. The host actively 
inhibits the translocation of the microbes into systemic sites (Slack et al. 
2009). However, many of their metabolic products enter the bloodstream and 
have systemic effects. The translocation of bacterial compounds depends on 
the integrity of the intestinal barrier, which can be weakened e.g., during 
infection by pathogens, stress or obesity (Soderholm and Perdue 2001, Brun 
et al. 2007, Groschwitz and Hogan 2009). Lipopolysaccharide (LPS), an 
endotoxin produced by Gram-negative bacteria, stimulates systemic 
inflammation and promotes adiposity, and may play an important role in 
metabolic diseases (Cani and Delzenne 2009). In a healthy microbiota, 
butyrate-producing Firmicutes (Peng et al. 2009), Akkermansia muciniphila 
(Everard et al. 2013), and bifidobacteria (Cani et al. 2007, Ewaschuk et al. 
2008) may improve the intestinal barrier function, which limits the amount 
of inflammatory bacterial antigens that pass into circulation. When these 
protective functions of the microbiota are disrupted, the microbiota may 
promote inflammation systemically. 
Apart from the above-mentioned processes, bacteria have a wide range 
of effects on the host, from vitamin production (LeBlanc et al. 2013) to the 
production of harmful substances from dietary compounds (Humblot et al. 
2007, Koeth et al. 2013) and even to influencing behaviour (Heijtz et al. 
2011). Studies on germ-free mice have revealed that the presence of bacteria 
has a profound impact on host phenotype, affecting all organ systems in the 
body (Evans et al. 2013). 
 
 
	   12	  
Microbiota analysis methods 
 
The intestinal microbiota are most conveniently and non-invasively surveyed 
from faecal samples. The faecal microbiota are representative of the colonic 
luminal community, while the bacterial composition in the mucosal layer and 
in the small intestine cannot be directly inferred from the faecal samples, but 
would require more invasive procedures (Zoetendal et al. 2002, Eckburg et al. 
2005). However, the majority of the intestinal bacteria reside in the large 
intestine, where most of their metabolic activities take place. Therefore, faecal 
samples are a useful source of information on the intestinal bacterial 
community. Traditionally, the composition of the microbiota was analysed by 
culture-based methods, which is labour-intensive, causes bias towards easily 
cultivated species, and the results are highly sensitive to culture conditions. 
Because of these difficulties, DNA-based methods, utilizing marker genes for 
taxonomic identification, are commonly used to characterise the microbiota 
(Table 1). Most large studies on infant microbiota have used qPCR, which is a 
targeted, non-global method, but due to the simplicity of the microbiota in 
young children, often suitable. Smaller studies have usually conducted next-
generation sequencing of variable regions on the 16S rRNA gene, which 
allows for comprehensive microbiota analysis. Infant microbiota studies 
abound, but studies with preschool or school age children are scarce (Table 1). 
 
Development of the intestinal microbiota in childhood 
 
The infant microbiome is simple, often dominated by a single species.  
Aerobic and facultative bacteria, such as staphylococci, streptococci, 
enterococci and enterobacteria are among the first colonizers (Palmer et al. 
2007, Bäckhed et al. 2015, Dogra et al. 2015a). Bifidobacteria, which are 
anaerobic, normally begin to increase in abundance a few days or weeks after 
birth (Eggesbo et al. 2011, Bäckhed et al. 2015, Dogra et al. 2015a). The infant 
microbiome is enriched in genes encoding enzymes for the utilization of milk-
derived glycans and the production of B vitamins (Bäckhed et al. 2015).  
However, even the fully breastfed infant has the microbial genetic potential 
for plant-derived polysaccharide degradation (Kurokawa et al. 2007, 
Vaishampayan et al. 2010, Koenig et al. 2011), which becomes necessary 
when solid foods are introduced. At weaning the microbiome responds to the 
change in diet by an increase in the abundance of Bacteroidetes and 
Clostridium clusters IV and XIVa, and a decline in Bacilli, Proteobacteria, and 
Actinobacteria (Koenig et al. 2011, Bergström et al. 2014, Bäckhed et al. 
2015). By the age of 2-3 years, children reach a community composition, 
which is distinct from the infant community, but has not yet reached an adult-
like composition (Ringel-Kulka et al. 2013, Korpela 2014). The development 
is gradual thereafter, and the adolescent microbiota composition still differs 
from that of adults (Agans et al. 2011).  
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Table 1.  Recent DNA-based studies on the microbiota of children. # refers to the number of 
samples per child, Birth, Diet, AB, and Phe indicate whether the study included information 
on birth mode, diet, antibiotics, and child phenotype. Metagenomics = sequencing the whole 
metagenome, 16S seq = sequencing parts of the 16S rRNA marker gene. TRFLP = terminal 
restriction fragment polymorphism analysis, qPCR = quantitate PCR, FISH = fluorescence in 
situ hybridisation. 
Ref Location Method N Age # Birth Diet AB 
Ph
e 
Yatsunenko 
et al. 2012 
America, 
Malawi 
Metagenomic
s  >0mo 1     
Tanaka et al. 
2009 Japan 
TRFLP, 
qPCR 26 0-2mo 5 x  x  
Dogra et al. 
2015a 
Singapore 16S seq 75 0-6mo 4 x x 
 
x 
Bäckhed et 
al. 2015 
Sweden 
Metagenomic
s 
98 0-12mo 3 x x 
  
Jakobsson et 
al. 2014 
Denmark 16S seq 24 0-24mo 6 x x x x 
Penders et 
al. 2006, 
2007 
Netherland
s 
qPCR 1000 1mo 1 x x x x 
Lee et al. 
2015 
Korea 16S seq 20 1mo 1 
 
x 
  
Fouhy et al. 
2012 Ireland 
16S seq, 
qPCR 18 1-2mo 2   x  
Fallani et al. 
2009 Europe FISH 606 1.5mo 1 x x x  
Azad et al. 
2013 Canada 16S seq 24 4mo 1 x x   
Nylund et al. 
2013 
Finland Microarray 34 6-18mo 2 
 
x 
 
x 
Bergström et 
al. 2015 
Denmark qPCR 300 9-36mo 3 x x 
 
x 
Persaud et 
al. 2014 
Canada 16S seq 184 12mo 1 x x x 
 
Ringel-Kulka 
et al. 2013 
US Microarray 28 1-4yr 1 
    
De Filippo et 
al. 2010 
Burkina 
Faso, Italy 
16S seq 29 1-6yr 1 
 
x 
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Factors influencing the early microbiota colonisation 
 
Many common practices, such as birth by Caesarean section, antibiotic use, 
lack of breastfeeding, and exposure to the hospital environment, influence the 
development of the infant’s microbiota (Biasucci et al. 2010, Dominguez-
Bello et al. 2010, van Nimwegen et al. 2011, Persaud et al. 2014, Bäckhed et 
al. 2015, Dogra et al. 2015a). In addition to the above-mentioned effects, 
there is large inter-individual, geographic and methodological variation in 
microbiota composition, which are often difficult to separate (Fig. 1). 
  An infant receives its genome from both parents, but the mother is 
most likely the main donor of the infant’s second genome, the microbiome. 
There is evidence that the early development of an infant’s microbiome is 
influenced by prenatal factors, suggesting that the colonization process 
depends strongly on maternal effects. The maternal intestinal and vaginal 
microbiomes have been shown to change during pregnancy, becoming less 
diverse and more dominated by typical infant-colonizing bacteria such as 
lactic acid bacteria (Aagaard et al. 2012, Koren et al. 2012). Several factors, 
such as excessive weight gain, antibiotic use, and stress, may interfere with 
the development of the microbiota during pregnancy and therefore with the 
transmission of bacteria to the infant. Overweight mothers harbour intestinal 
microbiota with low abundance of bifidobacteria and high abundance of 
enterobacteria and staphylococci (Collado et al. 2008, Santacruz et al. 2010), 
which is reflected in the infant’s early microbiota (Collado et al. 2010). The 
breast milk microbiome of overweight mothers also differs from that of 
normal weight mothers, indicating that the maternal guidance of the infant’s 
developing microbiome may depend on maternal weight (Collado et al. 2012), 
and may be involved in the inheritance of obesity (Woo and Martin 2015). 
The effects of maternal antibiotic use on the infant’s microbiome have not 
been thoroughly investigated, but maternal antibiotic use is known to 
increase the infant’s risk of childhood overweight (Mueller et al. 2015).  
  Prenatal stress affects the immunological and psychological 
development of the infant, predisposing to various diseases including asthma 
(Cookson et al. 2009) and increased childhood adiposity (Dancause et al. 
2015). In monkeys, prenatal stress has been found to influence the early 
development of the microbiome: the offspring of experimentally stressed 
females have a microbiome deficient in lactobacilli and bifidobacteria (Bailey 
et al. 2004). The mechanism is uncertain, but may be related to stress-
induced inflammation and increased levels of cortisol. Enterobacteria, unlike 
many other intestinal bacteria, are able to thrive in the intestine during 
inflammatory states (Lupp et al. 2007) and may benefit from potential stress-
associated inflammation, as well as the stress-associated hormones (Lyte et 
al. 1997). Furthermore, cortisol controls bile acid homeostasis (Rose and 
Herzig 2013), which directly regulates the microbiota (Islam et al. 2011).  
Caesarean section, which is unnecessarily common in many parts of 
the world (Zizza et al. 2015), affects the early microbial colonization of the 
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infant. Caesarean-born infants are first exposed to skin and hospital surfaces, 
rather than the birth canal, and consequently are colonized by bacteria 
residing on these surfaces, while vaginally born infants are colonized by 
vaginal and faecal bacteria of their mothers (Dominguez-Bello et al. 2010, 
Bäckhed et al. 2015). The normally dominant members of the infant intestinal 
microbiome, bifidobacteria, often show delayed development, and 
colonization by Clostridium difficile is more common than in vaginally born 
infants (Grönlund et al. 1999, Penders et al. 2006, Biasucci et al. 2010). In 
addition to bifidobacteria, Bacteroides spp. form a significant part of the 
vaginally born infant’s intestinal microbiota, but appear late in C-section born 
infants (Bäckhed et al. 2015). The microbiome differences between C-section 
born and vaginally born infants persist at least 6-12 months (Grönlund et al. 
1999, Bäckhed et al. 2015, Dogra et al. 2015a). However, the fact that C-
section-born infants generally develop normally and eventually reach a 
microbiota composition comparable to vaginally born infants indicates that 
major microbial colonisation and re-organisation occur after birth, guided by 
post-natal exposures. 
 
Breastfeeding 
 
Breastfeeding continues the maternal guidance of the developing microbiota 
by providing and nourishing specific bacteria (Grönlund et al. 2007, 
Marcobal et al. 2010, Garrido et al. 2012). The natural breastfeeding duration 
in humans is estimated to be 2-3 years, extending sometimes up to 6 years 
(Kennedy 2005). Although breastfeeding is known to promote the health of 
the infant and the mother (Labbok 2001, Hornell et al. 2013), modern 
children are often weaned before the age of 6 months (Callen and Pinelli 
2004). During pregnancy, microbial translocation from the intestine to the 
breast tissue increases, and breast milk contains many taxa that are 
commonly found in the infant intestine (Donnet-Hughes et al. 2010). Breast 
milk may therefore be a source of colonizing microorganisms.  
In addition to microbes, breast milk contains a rich cocktail of 
immunologically active compounds and cells. Formula-fed infants are 
essentially immune-deficient before the maturation of their own immune 
system, as they lack the maternally derived IgA, cytokines, hormones, 
leucocytes, human milk oligosaccharides (HMOs), and bactericidal enzymes 
present in breast milk (Hanson 1998, Hanson 2000, Newburg and Walker 
2007, Blustein et al. 2013). Indeed, breastfeeding is known to protect against 
infections in early life (Duijts et al. 2009, Abrahams and Labbok 2011, 
Hornell et al. 2013), and in pre-industrial times infant survival was strongly 
dependent on breastfeeding (Macadam and Dettwyler 1995).  
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Figure 1. Summary of recent early-life microbiota studies (data from papers in Table 1). Top 
panel: 1 month, middle panel: 3-4 months, and bottom panel: >6 month old infants. A = 
antibiotics, V= vaginal delivery, C = caesarean section; B = breastfed, F = formula-fed. 
Firmicutes are divided into clostridia  (including erysipelotrichi) and bacilli.
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Importantly, breast milk contains considerable amounts of various complex 
fucosylated and sialilated glycans that are non-nutritious for the host, but 
utilized as energy sources by Bifidobacterium, Bacteroides, and Akkermansia 
spp. in the infant intestine (Ward et al. 2006, Marcobal et al. 2011, Ottman 
2015). These glycans are not present in formula milk, and even 
oligosaccharide-supplemented or probiotic-supplemented formulas may not 
have the same effect on the infant microbiota as human milk (Euler et al. 
2005, Brunser et al. 2006). Maternal FUT2 genotype affects the composition 
of breast milk glycans, and infants of mothers with the inactive allele (non-
secretors) show delays in their acquisition of bifidobacteria and differences in 
bifidobacterium species composition (Lewis et al. 2015). This indicates that 
the mother guides the early development of her infant’s microbiota via breast 
milk. Breastfed infants often have higher abundances of bifidobacteria and 
lactobacilli and lower abundances of clostridia (including C. difficile), 
enterobacteria and enterococci than formula-fed infants (Ahrné et al. 2005, 
Euler et al. 2005, Brunser et al. 2006, Azad et al. 2013, Bergström et al. 2014, 
Bäckhed et al. 2015). The compositional differences are reflected in the 
functional differences: breastfed infants have more microbial genes coding 
vitamin B (e.g. folate) production (Bäckhed et al. 2015). The cessation of 
breastfeeding, rather than the introduction of solid foods, initiates a change in 
the microbiota towards an increased abundance of fibre-degrading Firmicutes 
and Bacteroidetes (Palmer et al. 2007, Bergström et al. 2014), which form the 
majority of the adult microbiota. 
 
Antibiotics and probiotics 
 
Antibiotics account for the majority of prescription medication used by 
children in western countries (Chai et al. 2012). Several human studies have 
shown dramatic changes in the intestinal microbiota of adults in response to 
oral antibiotic treatments (De La Cochetiere et al. 2005, Dethlefsen et al. 
2008, Jakobsson et al. 2010, Jernberg et al. 2010, Dethlefsen and Relman 
2011). In adults, the intestinal microbiota usually, but not always, recover 
after discontinuation of the antibiotic treatment. However, in infants, 
perinatal antibiotic use is associated with changes in the intestinal microbiota 
composition persisting for up to 1 year (Persaud et al. 2014), indicating that 
early-life antibiotic use may permanently disturb the colonization process. In 
the short term, infants with antibiotic exposure often have reduced 
abundance of bifidobacteria, normally the dominant member of the infant 
microbiota, and increased abundance of potentially inflammatory bacteria 
such as E. coli  (Penders et al. 2006, Tanaka et al. 2009, Fallani et al. 2010). 
Probiotics are defined as live microorganisms that when administered 
in adequate amounts confer a health benefit on the host (Hill et al. 2014). 
Lactic acid bacteria and bifidobacteria are among the most commonly used 
probiotics. Lactobacillus rhamnosus GG is one of the best-studied strains 
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marketed as a probiotic (Saxelin et al. 2005).  Extensive meta-analyses have 
shown this bacterium to be effective in the treatment of many gastrointestinal 
illnesses in children: it reduces gastrointestinal pain (Horvath et al. 2011), 
Clostridium difficile -associated diarrhoea (Segarra-Newnham 2007), 
healthcare-associated diarrhoea (Szajewska et al. 2011), antibiotic-associated 
diarrhoea (Hawrelak et al. 2005), and the duration of infectious diarrhoea 
(Szajewska et al. 2007). In adults, probiotic use has not resulted in large 
changes in faecal microbiota composition (Kim et al. 2013, Lahti et al. 2013a). 
This suggests that the mode of action may be related to altered microbial 
metabolism or direct interaction with the host (Gerritsen et al. 2011). L. 
rhamnosus GG produces pili with the mucus-binding protein SpaC 
(Kankainen et al. 2009). These pili have been shown to be important for the 
adhesion of the bacteria to mucus and to enable close contact with intestinal 
cells and effective stimulation of the immune system (Lebeer et al. 2010, 
Gerritsen et al. 2011).  
 
Health effects of the early microbiome development 
 
The early development of the microbiome is emerging as a key factor involved 
in the immunological  (Grönlund et al. 2000, Sjögren et al. 2009, Russell et 
al. 2012) and metabolic (Cox et al. 2014) programming of the host, with 
potential long-term health impacts (Reinhardt et al. 2009, Willing et al. 2011, 
Scholtens et al. 2012). The factors affecting the early microbiome 
development, such as delivery by Caesarean section (Bager et al. 2008, 
Cardwell et al. 2008, Thavagnanam et al. 2008, van Nimwegen et al. 2011, 
Mueller et al. 2015), lack of breastfeeding (Harder et al. 2005, Hornell et al. 
2013), prenatal stress (Dancause et al. 2015, Hohwü et al. 2015), and early-
life antibiotic use (Hviid et al. 2011, Virta et al. 2012, Mueller et al. 2015, 
Saari et al. 2015, Gerber et al. 2016) have been associated with increased 
incidence of various metabolic and immunological conditions, such as 
increased weight gain, overweight, asthma, type 1 diabetes, celiac disease, and 
inflammatory bowel disease (IBD). The type of antibiotic and the timing of 
the course appear to be important for later metabolic effects (Saari et al. 2015, 
Gerber et al. 2016). The increased risk for allergic diseases in C-section born 
infants has been shown to be associated with an increased abundance of C. 
difficile in early life in a large Dutch infant cohort (van Nimwegen et al. 2011). 
Animal experiments have demonstrated that early-life antibiotic use disrupts 
the microbiota and consequently immune function, predisposing to the 
development of asthma (Noverr et al. 2005, Russell et al. 2012).  
In production animals, antibiotic use increases weight gain at least 
partly by suppressing subclinical infections (Dibner and Richards 2005). In 
laboratory mice, the antibiotic-induced weight gain was demonstrated to 
result from the altered gut microbiome (Cox et al. 2014). Epidemiological 
studies have confirmed the positive relationship between antibiotic use and 
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weight gain in humans (Thuny et al. 2010, Ajslev et al. 2011, Trasande et al. 
2013, Gough et al. 2014, Saari et al. 2015, Gerber et al. 2016) and indicated 
that even prenatal antibiotic exposure predisposes to childhood overweight 
(Mueller et al. 2015). This suggests that maternal microbes may play a 
significant role in the metabolic programming of the infant. Pre- and 
perinatal maternal and environmental factors are being recognized as 
important contributors to the long-term metabolic programming and weight 
development of infants, and multiple lines of evidence indicate that childhood 
overweight may be strongly dependent on early-life exposures (Cottrell and 
Ozanne 2008). The intestinal microbiota, acquired initially during birth from 
the mother and nurtured by breast milk, are emerging as an important 
modulator of early metabolic programming, with long-lasting health 
consequences. 
 
Paediatric inflammatory bowel disease 
 
One of the most extreme examples of aberrant microbiota development is 
inflammatory bowel disease (IBD), a term encompassing Crohn´s disease 
(CD), ulcerative colitis (UC) and unclassified colitis (IBDU). The incidence of 
paediatric IBD is rapidly increasing in Europe and North America (Benchimol 
et al. 2011). In Finland the incidence of paediatric IBD has increased by 5-8% 
annually, reaching 15/100 000 in 2003 (Lehtinen et al. 2011). The incidence 
of UC has continued to increase since (Jussila et al. 2012). The causes of IBD 
are unknown. Several genes involved in immune defence are associated with 
disease risk, but their total effect is fairly small (Jostins et al. 2012). 
Childhood environment and exposures have been shown to predict IBD 
incidence (Gearry et al. 2010), and common to these predictive factors is that 
they influence the intestinal microbiota. The interactions between the 
immune system and intestinal microbiota are most likely of central 
importance in the aetiology of IBD (Jostins et al. 2012). Disturbed microbiota 
development, caused possibly by frequent antibiotic use, lack of 
breastfeeding, Caesarean birth or dietary patterns, may lead to the 
development of inflammatory microbiota, to which the immune system reacts 
aggressively in genetically susceptible individuals (Gearry et al. 2010, Kostic 
et al. 2014).  
The microbiota in paediatric IBD patients is often characterized by 
increased abundance of Gram-negative organisms and decreased abundance 
of butyrate-producers (Schwiertz et al. 2010, Papa et al. 2012). An increased 
abundance of bacteria, particularly Gram-negative bacteria, in the gut mucosa 
has been observed, suggesting a failure at the mucosal barrier (Conte et al. 
2006). Some studies find an increase in Bacteroides (Schwiertz et al. 2010), 
while other report an increase in enterobacteria (Papa et al. 2012, Gevers et 
al. 2014), suggesting that the IBD-associated microbiota may take different 
shapes. 
	   20	  
The treatment of IBD is currently centred on calming the immune 
response, using anti-inflammatory drugs such as 5-aminosalisylic acid, 
corticosteroids, immunomodulatory drugs, and reducing the abundance of 
bacteria in the intestine by antibiotics. Antibiotics have, however, been shown 
to aggravate rather than improve the dysbiosis associated with IBD (Gevers et 
al. 2014), and antibiotic use is a risk factor for IBD (Virta et al. 2012). The use 
of TNF-α-antagonists is becoming increasingly common in the treatment of 
severe paediatric IBD patients, and many patients respond positively. TNF-α 
is a pro-inflammatory cytokine, produced by activated macrophages and 
other immune cells. When bound to its receptor, TNF-α actives signalling 
cascades leading to a range of outcomes from immune responses to apoptosis 
or cell proliferation (Chen and Goeddel 2002). Its expression is increased in 
inflamed mucosa. However, nearly half of patients show no response, require 
dose escalation, or lose the response (de Bie et al. 2012). The reasons for this 
are currently unknown and response cannot be predicted (de Bie et al. 2012). 
The use of TNF-α-antagonists carries the risk of adverse effects, and is very 
expensive, and therefore selecting patients with a high likelihood of benefiting 
from the treatment would be important, but is currently not possible. 
Aims of the thesis 
 
This thesis aims to characterize the development of the human intestinal 
microbiota in healthy children and to identify factors, which are important for 
the natural development of the microbiota. Specifically, the influence of four 
common factors potentially modulating the microbiota – prenatal stress, 
breastfeeding duration, antibiotic use, and probiotic use – is investigated, as 
well as the association between early-life microbiota composition and the 
development of BMI. In addition, the microbiota in healthy children is 
contrasted with that that of children with IBD, characterising the association 
between treatment response and microbiota in IBD. 
Material and Methods 
Study cohorts 
 
The data for paper I is derived from the Dutch BIBO study, which is a 
longitudinal study following 193 mothers and their children from the third 
trimester of pregnancy on (Beijers et al. 2011). Pregnant women were 
recruited through midwife practices in Nijmegen and surrounding areas (the 
Netherlands).  A sub-cohort of 56 infants was selected for this study based on 
the availability of their faecal samples and their exposure to prenatal stress. 
All infants were healthy, born at full term (≥ 37 weeks) and had a 5-min 
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APGAR score ≥ 7. Caesarean-delivered children were excluded. Five faecal 
samples were collected from the infants from birth until ±115 days of life.  
 
Table 2. Study cohorts. Microbiota refers to the number of children providing microbiota 
samples. Other response indicates how many children provided other response variables 
(specified below). 
 
Country Age 
Micro
biota 
Other 
resp. 
Samples
/subject 
DNA 
extr. 
Analysis 
platform 
I Netherlands <5 months 56 56 3-5 RBB HITChip 
II Finland 2-7 years 142 226 1-2 Pro 454 
III Finland 2-7 years 142 236 1-2 Pro 454 
IV Finland 2-7 years 88 231 2 Pro HITChip 
V 
Netherlands  & 
Finland 3 months 162 162 1 RBB HITChip 
VI Finland 12-18 years 94 94 1-3 RBB HITChip 
RBB = repeated bead beating. Pro = enzymatic lysis procedure and subsequent purification 
using the Promega Wizard Kit (see Salonen et al. 2010 and Ahlroos & Tynkkynen 2009 for 
details). 
 
Data for papers II-IV originate from a probiotic trial (Kumpu et al. 2012). The 
children were recruited at day care centres in northern Finland. The probiotic 
treatment group received milk supplemented with Lactobacillus rhamnosus 
GG (LGG; approximately 106 cfu/ml), and the control group received similar 
milk without the probiotic. The intervention continued for seven months. All 
participants attended a health check and were asked to provide a faecal 
sample at the beginning and end of the intervention period. Originally a total 
of 501 children participated in the study; for the microbiota studies, subsets 
were selected based on the availability of the relevant records and samples 
(Table 2).  
For paper V, data from the BIBO cohort (N=87, based on availability of 
faecal samples and weight data) were combined with data from a Finnish 
infant study (N=75). The Finnish study was a large synbiotic trial involving 
ca. 1000 infants (Kuitunen et al. 2009), from which a sub-cohort was selected 
for the study from the vaginally born control group, based on availability of 
faecal samples and weight data. 
For study VI, we invited 12-18 year old Finnish-speaking patients with 
IBD treated at the Children’s hospital, Helsinki, to provide faecal samples for 
microbiota and calprotectin analyses. Age-matched healthy adolescents, and 
patients with juvenile idiopathic arthritis were invited as controls. IBD 
patients with acute severe colitis were excluded. One faecal sample was 
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analysed for most subjects, but a subset of 11 patients, beginning TNF-α-
therapy, provided a faecal sample before, after 2 weeks and after 6 weeks 
from starting the therapy. 
Written informed consent was received from the parents of all children 
participating in the studies. All studies were approved by the local ethical 
committees. 
 
Analysis of the intestinal microbiota using faecal samples 
 
DNA was extracted from the faecal samples using either the repeated bead 
beating (RBB) method, which relies on mechanical and chemical lysis of cells, 
as described previously (Salonen et al. 2010), or a modified version of the 
Promega Genomic Wizard DNA Purification Kit (Promega, Madison, WI, 
USA; Ahlroos and Tynkkynen 2009). In the Promega protocol, the 
purification of DNA is based on sequential precipitation of proteins and 
nucleic acids. Both methods have been shown to result in comparable 
microbiota compositions (Salonen et al. 2010). The bacterial composition was 
studied using two methods, a phylogenetic microarray, the Human Intestinal 
Tract Chip (HITChip) (papers I, IV, V, VI) as well as 16S rRNA gene amplicon 
sequencing using the Roche 454 pyrosequencing platform (papers II, III). 
The HITChip is specifically designed for the analysis of the human intestinal 
microbiota (Rajilic-Stojanovic et al. 2009). The microarray consists of 
oligonucleotide probes targeting hyper-variable regions V1 and V6 of the 16S 
rRNA gene, allowing the identification, quantification and phylogenetic 
positioning of not only previously cultured and named, but also uncultured 
bacterial phylotypes.  Microarray analysis of the bacterial DNA was conducted 
by collaborators in Wageningen, the Netherlands, as described (Rajilic-
Stojanovic et al. 2009). Briefly, the DNA was amplified with PCR using the 
universal bacterial primers T7prom-Bact-27-for and Uni-1492-rev. The DNA 
was then transcribed to RNA, which was labelled and hybridized on the 
microarray.  The signal intensities of the oligonucleotide probes were 
translated into abundances of 1038 species-level phylotypes, 130 genus level-
taxa, and 23 phylum-level taxa and clostridium clusters using the fRPA pre-
processing algorithm (Lahti et al. 2013b). The genus-level taxonomy was 
formed by grouping together related (>90% genetic similarity) organisms. 
The groups were named according to the nearest cultured relative. The 
microbiota data were transformed into relative abundances by dividing the 
signal intensities of each taxon by the total signal intensity of the sample. 
Sequencing of the V4-V6 hypervariable region of the 16S rRNA gene 
was conducted using the 454 Titanium pyrosequencing on a GS FLX (Roche 
Diagnostics) instrument, using the primers S-D-Bact-0564-a-S-15/S and 
Univ-1100-a-A-15, which have high coverage among bacteria (Klindworth et 
al. 2013). The sequences were filtered for chimaeras with the Uchime 
program (Edgar et al. 2011). Reads shorter than 501 nucleotides and samples 
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with <1000 reads were filtered out. After pre-processing, we had a total of 
2,262,107 reads from 257 samples (on average 8801 reads/sample, range 
1469-14653 reads/sample). De novo OTU picking was done using Qiime 
(Caporaso et al. 2010). To avoid batch effects, we normalized the data 
following a method we have developed earlier (Korpela et al. 2014). 
In addition, for paper III, functional profiling of the microbiome was 
conducted. Whole genome metagenomic sequencing was conducted by 
collaborators at the European Molecular Biology Laborary, Germany, on a 
subset of 20 samples using the Illumina HiSeq platform. The metagenomic 
analysis was used as a discovery tool to guide further qPCR-based analyses on 
a larger number of samples. Based on the metagenomic results, real-time 
qPCR was conducted to measure bile-salt hydrolase genes and antibiotic 
resistance genes. In addition, bacteria from the faecal samples were cultured 
anaerobically to test for antibiotic susceptibility of the bacterial communities. 
 
Other sources of data 
 
For paper I, stress experienced by the mothers during the third trimester of 
pregnancy was recorded in two ways: validated questionnaires measuring 
different types of stress, and salivary cortisol levels measured at different 
times of the day.   
Papers II-IV included antibiotic purchase records, obtained from the 
national drug purchase registry maintained by Kela (the Finnish Social 
Insurance Institute). All reimbursed drug purchases, which is estimated to 
cover >95% of antibiotic purchases, are recorded in the registry, as well as the 
diagnoses for chronic illnesses. Paper II utilized questionnaire-based data on 
the duration of breastfeeding, as well as weight and height of the children 
measured during a physician’s visit at the beginning of the study. Paper III 
included the registry-based information on chronic illnesses and weight and 
height data.  
In paper V, the children were measured for weight and height at the 
age of 5-6 years. In addition, information on their antibiotic use was obtained 
from clinical records and questionnaires. 
For study VI, faecal calprotectin was measured in a routine clinical 
laboratory using a quantitative enzyme immunoassay, as an indication of 
disease activity. In addition, patient records including diagnosis, location of 
disease, history or surgery, diet, antibiotic and probiotic use were available. 
 
Statistical methods 
 
Univariate analyses were conducted using general linear or generalized linear 
models, depending on the response variable. Normally distributed response 
variables were analysed with linear regression or analysis of variance models; 
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count variables were analysed with generalized linear models, using the 
negative binomial distribution. Fixed effects models were used when only one 
time point for each individual was analysed and mixed effects models with 
subject as random factor, when multiple samples were analysed from the 
same individuals. Potentially confounding variables such as probiotic use, 
age, and BMI were included as covariates in the models. Multivariate analyses 
were conducted with principal coordinates analysis (PCoA), usually using the 
Bray-Curtis dissimilarities, hierarchical clustering, and multivariate 
permutational analysis of variance. All statistical analyses were conducted in 
R (R Core Team 2012), using the packages vegan (Oksanen et al. 2013), MASS 
(Venables and Ripley 2002), glmmADMB (Skaug et al. 2012), and nlme 
(Pinheiro et al. 2013). 
Results and Discussion 
Microbiota development during the first years of life 
 
Combining different data sets of altogether 222 healthy children, it is possible 
to roughly characterize the general pattern of microbiota development during 
the first 6 years of life (Fig. 2). While there are marked individual differences 
in the development, on average the development tends to progress through 
three distinct phases: successional phase 1 is represented by a dominance of 
Bacilli, mainly staphylococci, streptococci, and enterococci. This phase begins 
a few days after birth and is estimated to last in general for 2-3 weeks, when 
bifidobacteria become the most abundant group. The dominance of 
bifidobacteria represents the second successional phase, and continues until 
about 1 year of age. During the first two phases, Proteobacteria represent a 
relatively abundant taxon, on average 10% of the microbiota. At the age of 
approximately 6 months, the abundance of bifidobacteria and Proteobacteria 
begin to decline, and the abundance of Clostridium clusters (hereafter 
‘clostridia’, referring collectively to the Firmicutes classes Clostridiaceae, 
Erysipelotrichaceae and Ruminococcaceae) and Bacteroidetes begin to 
increase gradually. By the age of approximately 1 year, bifidobacteria, 
although still very abundant, have been replaced by clostridia (mainly 
Clostridium cluster XIVa) as the most abundant bacterial group, which marks 
the initiation of the third successional phase. During this phase, clostridia 
continue to increase in abundance, reaching a relative abundance of 50% at 
approximately 2 years, and the infant-type taxa, Bacilli, Proteobacteria, and 
bifidobacteria, decline to <10% by the age of 6 years. The timing of the 
transition from phase 2 to phase 3 likely depends on the timing of weaning 
(Koenig et al. 2011, Bergström et al. 2014, Bäckhed et al. 2015), but what 
induces the transition from phase 1 to phase 2 is not well known. These 
results are averages based on 455 samples from a cohort of 222 children 
originating from two European countries, but they appear to be fairly general 
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among healthy, vaginally born, breastfed children (Dogra et al. 2015b). 
Similar patterns appear to occur in non-European children, especially with 
regard to bifidobacteria (De Filippo et al. 2010, Yatsunenko et al. 2012). 
However, individual variation in the timing of the phases is considerable and 
likely to be of importance for the metabolic and immunological programming 
of the child. 
 
 
Figure 2. Microbiota development during the first 6 years of life (x-axis is on log-scale). The 
figure shows averages based on 455 faecal samples of 222 children of different ages. 
 
Maternal stress during pregnancy is associated with the 
infant’s early microbiota development (I) 
 
Maternal pregnancy-related stress was strongly associated with the early 
development of the infant’s intestinal microbiota (I), slowing the transition to 
a Bifidobacterium-dominated composition (Fig. 3). Together, two stress-
indicators, experienced pregnancy-related stress and salivary cortisol showed 
associations with 78% of the genus-level bacterial groups in the infants, and 
prenatal stress was comparable to feeding type (breastfed or formula-fed) in 
terms of the strength of the microbiota association. The results suggest that 
maternal stress, or something co-occurring with maternal stress, is a major 
contributor to the early development of the microbiota. Cortisol levels and 
reported stress were only modestly correlated, indicating that they measure 
different types of stress. However, they appeared to have similar and additive 
effects on the microbiome: infants born to mothers with high reported stress 
and high cortisol had the most divergent microbiota development, compared 
to infants born to mother with low levels of both stress indicators. The infants 
born to mothers with one high and one low indicator had an intermediate 
microbiota composition. The bacterial taxa most strongly associated with 
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prenatal stress were bifidobacteria and lactobacilli, both of which were 
significantly reduced in the high stress group, and enterobacteria and 
enterococci, which were significantly increased (Fig. 3).  
As this study is descriptive, the mechanism behind the observed 
association cannot be delineated. The altered infant microbiota may be 
caused by changes in maternal microbiota, or changes in the infant’s 
physiology. In favour of the former hypothesis speak the observation that the 
abundance of Proteobacteria increases during pregnancy in some, but not all, 
mothers (Koren et al. 2012), and the composition of infant meconium is 
characterized by dominance of either lactobacilli or Proteobacteria (Gosalbes 
et al. 2013). Whether the maternal microbiota composition correlates with 
maternal stress, and translates to a higher abundance of Proteobacteria and 
lower abundance of lactobacilli and bifidobacteria in the infant’s intestine, is 
yet to be confirmed. However, in mice, exposure to as little as 2 hours of 
stress alters the colonic mucosal microbiota, reducing the abundance of 
lactobacilli (Galley et al. 2014).  
Stress is strongly related to inflammation: both psychological and 
physiological stress may induce inflammation also in the intestinal mucosa, 
and vice versa, inflammation may induce stress (Black 2002). Stress may thus 
directly affect the microbiota of the mother, and maternal transmission of 
bacteria. This pathway may lead to a selection of bacteria tolerant of 
inflammation and stress hormones, such as the enterobacteria (Lyte et al. 
1997, Lupp et al. 2007), which were elevated in the stress-exposed infants. 
Stress may also influence bile acid levels, as cortisol is known to control bile 
acid production in the liver, and regulate cholesterol and bile acid 
homeostasis (Rose and Herzig 2013), thus influencing the maternal 
microbiota (Islam et al. 2011). Furthermore, maternal stress may influence 
her lifestyle (e.g., diet, sleep, exercise), which is likely to affect her microbiota. 
It is also possible that the maternal stress correlates with or is dependent on 
some other factor that also alters the infant microbiota. Furthermore, reverse 
causation is possible: inflammation is known to regulate glucocorticoid 
secretion, and LPS produced by the intestinal microbiota may activate the 
HPA axis (Black 2002). Microbiota-derived inflammation in the mother may 
thus affect her stress measurements, in which case maternal stress and the 
infant microbiota would both be dependent on the maternal microbiota.  
Although causation cannot be established in observational human 
studies, experiments with non-human primates show a very similar effect of 
prenatal stress on the microbiota (Bailey et al. 2004), which suggest that the 
effect is causal and fairly universal. Both the stress response and the 
inflammation response are highly conserved across the animal kingdom 
(Maier and Watkins 1998), and it is possible that the response of the host-
associated microbiota to stress and possibly inflammation may be equally 
conserved. If so, the apparent negative effects observed in prenatally stressed 
infants could be adaptive and shaped by evolution. It is possible that prenatal 
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stress prepares the infant to cope in a stressful environment, and changes in 
the microbiota may be involved in the early programming.  
 
 
Figure 3. The development of the relative abundance of selected bacterial groups during the 
first 4 months of life in low prenatal stress (A) and high prenatal stress (B) infants in paper I. 
The panels show the best-fit lines (based on linear 3rd polynomial models) and standard 
errors. The average relative abundance of the main bacteria phyla, Firmicutes divided into 
bacilli and clostridia, at 3 months of age is shown below the panels. 
 
Breastfeeding duration is associated with long-term 
microbiota development (II) 
 
Among the 2-7 year old Finnish cohort, the duration of breastfeeding was 
associated with the microbiota composition, when the effect of other factors 
such as health and antibiotic use were eliminated (II). A clear distinction in 
the microbiota composition was evident between children breastfed for 0-6 
months and those breastfed for 8-16 months: the abundance of bifidobacteria 
and Akkermansia were significantly higher, and the abundance of clostridia 
significantly lower among the children with longer breastfeeding duration, 
indicating a slow transition from phase 2 to phase 3 (Fig. 4). Bifidobacterium 
spp. and Akkermansia muciniphila are known to specialize in host-glycan 
utilization and both genera contain species with the ability to degrade mucin 
(Derrien et al. 2004, Ruas-Madiedo et al. 2008). Several Bifodobacterium 
spp. are capable of growing in breast milk (Zivkovic et al. 2011), as has also 
been found for Akkermansia muciniphila (Ottman 2015).  
Although we matched the children based on age, antibiotic use history, 
and BMI, we cannot exclude the possibility that some of the observed effects 
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of breastfeeding may have been due to potential confounding effects of birth 
mode, infant birth weight, lifestyle, diet, maternal education, or maternal 
BMI (Riva et al. 1999, Scott et al. 2001, Bertini et al. 2003, Cernadas et al. 
2003, Wojcicki 2011). 
 
Antibiotic use is associated with microbiota development (II, 
III) 
 
Early-life antibiotic use appeared to interfere with the development of the 
infant’s microbiota and to disrupt the maternal guidance via breast milk (II). 
Children who had been weaned late but had antibiotic courses before weaning 
had at 2-7 years of age a microbiota composition similar to those with short 
duration of breastfeeding (Fig. 4), particularly with respect to the abundance 
of bifidobacteria and clostridia. The transition from successional phase 2 to 3 
was thus faster in the children who had received antibiotics during their early 
life, regardless of breastfeeding duration (II). Children who had received 
antibiotics before weaning or shortly after had an increased abundance of 
Bacteroidetes (mainly Bacteroides spp.) at the age of 2-7 years compared to 
those who did not receive antibiotics in early life (II).  
Antibiotic use continued to affect the microbiota development in later 
childhood (III). The microbiota composition in children exposed to penicillin 
or macrolide –type antibiotics during the 2 years before faecal sample 
donation was compared the composition in children with no recent 
antibiotics and low lifetime antibiotic use. The most dramatic apparent effect 
of antibiotic treatment was the decline in the relative abundance of 
Bifidobacterium after a macrolide course (Fig. 5), which normalized within 2 
years. As bifidobacteria declined, the relative abundances Bacteroidetes and 
Firmicutes were elevated after a macrolide course; the increase in 
Bacteroidetes was highly significant and consistent between individuals. The 
abundance of Firmicutes was strongly dependent on age, and the antibiotic 
effect was not statistically significant in the total cohort. 
Bacteroides spp. were thus elevated if the child had received 
antibiotics in early life, or if the child had recently received macrolides, 
suggesting that Bacteroides spp. may benefit from the antibiotic-induced 
disruption of the normal microbial balance. The abundances of Collinsella, 
Lactobacillus, and Anaerostipes, as well as the total richness and maturity of 
the microbiota, also remained reduced for up to 2 years after a macrolide 
course. Furthermore, macrolide resistance was increased and the abundance 
of bile-salt hydrolase genes decreased after macrolide treatment. The former 
observation is indicative of causality and demonstrates that antibiotic use 
promotes antibiotic resistance within the individual; the latter indicates that 
antibiotic use may alter bacterial metabolism of host-affecting biomolecules, 
potentially influencing the microbiota-host interaction.  
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Figure 4. Relative abundance of selected bacterial groups in children breastfed for 8-16 
months without antibiotics (Long/AB-), 0-6 months without antibiotics (Short/AB-), and 8-
16 months with antibiotics (Long/AB+). Data from paper II. The bars show the group means 
and the whiskers show the standard errors. The average relative microbiota composition in 
the three groups is shown on the lower panel. 
 
Recent penicillin or amoxicillin use had partly different and clearly weaker 
overall association with the microbiota than macrolide use (Fig. 5). 
Indications for the different antibiotic types did not differ: both macrolide 
and penicillin-type antibiotics were mostly prescribed for respiratory 
infections. This suggests that the antibiotics, and not the illness that 
prompted their use, caused the patterns observed in the microbiota. Previous 
mouse experiments support our results, and indicate that the observed effects 
of antibiotics on the microbiota are likely to be causal. A reduction in bile-salt 
metabolism has been observed in mice experimentally treated with 
streptomycin (Antunes et al. 2011). Early-life treatment with penicillin and 
macrolide –type antibiotics has been shown to alter the microbiota of mice in 
a similar way (Nobel et al. 2015), as seen here in children.  
The differences between the antibiotics in their apparent effects on the 
microbiota are likely due to the differences in mechanism of action, spectrum 
of susceptible organisms, and pharmacokinetics. Penicillin-type antibiotics 
are betalactams, which kill bacteria by inhibiting cell wall synthesis. The beta-
lactam ring binds to peptidoglygan in the bacterial cell wall, inhibiting cross-
linking between peptidoglycan chains. Beta-lactams tend to be more effective 
against Gram-positive bacteria, while Gram-negative bacteria with the outer 
membrane protecting the peptidoglycan structure, are often less susceptible. 
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To be effective, betalactams need to be maintained at a sufficient 
concentration over time. Penicillins are well absorbed from the small 
intestine and excreted via urine. Therefore their concentration in the colon is 
likely to be mostly too low for strong bactericidal effects, particularly against 
Gram-negative organisms.  
 
 
 
Figure 5. Antibiotic use and phylum-level microbiota. Data from paper III. Top panel shows 
the association between the abundance of the dominant phyla and time since the most recent 
macrolide course (locally averaged smooth fit with standard errors). Bottom panel shows the 
average relative microbiota composition in children with a macrolide course (M) or penicillin 
course (P) <6 months ago, and children with no antibiotics for >2 years (CTRL). 
 
Macrolides inhibit bacterial protein synthesis in bacterial cells by binding to 
the 50S-ribosome subunit. To be effective, they need to permeate the cell wall, 
which renders many Gram-negative bacteria resistant due to their cell wall 
structure. Macrolides concentrate in macrophages, and in many tissues and 
excretions, such as saliva and stomach (Scholar & Pratt 2000). Furthermore, 
macrolides are metabolised in the liver and excreted in bile, often undergoing 
enterohepatic cycling. These characteristics mean that that macrolides may 
reach high concentrations in the intestine (Scholar & Pratt 2000). They have 
a long half-life, so their effect may last longer than that of penicillins. 
Macrolides are thus more likely to reach sufficiently high concentrations in 
the intestine for sufficint periods of time to have negative effects on the 
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microbiota. Macrolides also have a range of effects on host cells (Kanoh & 
Rubin 2010).  
A full recovery of the microbiota from an antibiotic course appeared to 
take longer than the average interval between courses (the children received 
on average 1.8±1.5 courses/year). This suggests that many children may not 
fully recover from antibiotic disturbance, but are in a continuously disrupted 
state throughout their early life. Whether this continuously distorted 
microbiota composition in childhood has any permanent life-long effects on 
the microbiota composition or function is currently not known, but mouse 
studies indicate that even temporary disruption of the microbiota in early life 
has long-term metabolic consequences (Cox et al. 2014). 
 
L. rhamnosus GG alleviates penicillin-associated changes in 
the microbiota (IV) 
 
The results have shown that antibiotic use is a major determinant of 
microbiota development and composition in children. A potential solution to 
mitigate the effects of antibiotics on the microbiota is probiotic use. However, 
its efficacy in preventing antibiotic-associated microbiota disturbance in 
children has not been clearly demonstrated. Furthermore, the consequences 
of long-term probiotic use on the microbiota of children have not been 
investigated. We found that long-term daily probiotic consumption altered 
the microbiota composition of children, but did not appear to have any 
detrimental effects. The observed changes occurred largely among the 
bacteria residing in the small intestine: several species of lactic acid bacteria 
increased in abundance, while the relatives of E. coli decreased (Fig. 6). This 
may be a beneficial change, as many species related to E. coli are potentially 
pathogenic and produce the inflammatory lipopolysaccharide (LPS) (Raetz 
and Whitfield 2002). However, such changes have not been observed in 
previous studies with adults (Kim et al. 2013, Lahti et al. 2013a), indicating 
that the adult microbiota may be more resistant to modulation than the 
developing microbiota of preschool children, or that long-term 
supplementation is necessary for changes in the microbiota to occur. 
Importantly, the probiotic treatment prevented many of the penicillin-
associated changes in the microbiota such as the increase in E. coli and 
Haemophilus (Fig. 6). However, the macrolide-associated reduction in 
bifidobacteria was not prevented by LGG consumption. Previously, 
Lactobacillus acidophilus-Bifidobacterium spp. supplementation in adults 
during H. pylori eradication therapy (amoxicillin-clarithromycin-
lansopratzole) and during amoxicillin treatment has been shown to prevent 
some of the antibiotic-associated changes in the microbiota (Plummer et al. 
2005). Our results show that one lactobacillus strain alone is not sufficient to 
prevent the microbiota changes associated with all antibiotic types; different 
species may be efficacious in association with different types of antibiotics. 
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Figure 6. Change in relative abundance of selected bacterial taxa from baseline to the end of 
the intervention in children treated with different combinations of antibiotics (P = penicillin, 
M = macrolide) and probiotic (LGG = Lactobacillus rhamnosus GG) during the intervention 
(paper IV). The bars show the group means and the whiskers show the standard errors. 
 
Breastfeeding and probiotic use may prevent infections (II, 
IV) 
 
Long duration of breastfeeding was associated with reduced rate of infections 
(mainly respiratory infections) throughout the preschool age, as indicated by 
reduced antibiotic use (II). However, if the child received antibiotics during 
breastfeeding or shortly after weaning, the protective effect of breastfeeding 
was weaker. These results suggest that part of the long-term protection 
against infections conveyed by long breastfeeding is attributable to the 
beneficial effects of breast milk on the microbiota. In support of these results, 
we discovered that daily consumption of LGG significantly reduced the 
infection rate of preschool children for up to three years after the cessation of 
the probiotic trial (IV).  
The observed protective effects of breastfeeding and LGG 
supplementation are in concordance with current knowledge on the 
immunomodulatory capacity of lactic acid bacteria. Several strains of 
lactobacilli and bifidobacteria have been shown to regulate systemic 
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immunity in animals and humans (reviewed in Cross 2002, Vouloumanou et 
al. 2009). The host’s immune cells sample the microbiota and respond to 
microbial signals. Bacterial metabolites and components, such as the cell-wall 
peptidoglycan, can elicit immune cell activation, immunoglobulin production, 
and cytokine production. Administration of probiotic strains has been shown 
to strengthen immune responses in the gut against specific enteric pathogens, 
but also in extra-intestinal mucosal sites non-specifically against viral and 
bacterial pathogens (reviewed in Cross 2002, Vouloumanou et al. 2009).  In a 
previous study on daycare-attending children, analogous to our LGG-
supplementation study, LGG supplementation was shown to reduce the 
frequency of respiratory infections during the intervention (Hatakka et al. 
2007). 
Together these results suggest that certain strains of bacteria, such as 
LGG taken as a supplement and those promoted naturally by breastfeeding, 
may regulate the development of the immune system and hence contribute to 
the life-long immunological programming occurring in early life (Martin et al. 
2010). This suggests that LGG supplementation may help particularly those 
children who did not receive sufficient breast milk for optimal immune 
development, or who were given antibiotics during the breastfeeding period.  
 
Microbiota and metabolic programming (II, III, V) 
 
Long duration of breastfeeding appeared to protect against high BMI in later 
childhood, but only among the children who did not receive antibiotics before 
weaning or immediately after (II). This suggests that the protection against 
overweight endowed by breastfeeding, which has been shown in several 
cohorts (Metzger and McDade 2010), is microbiota-dependent, and that 
antibiotic use may disrupt the beneficial metabolic effects of breastfeeding. 
This also offers an explanation to the controversy regarding the metabolic 
benefits of breastfeeding (Owen et al. 2005); antibiotic use has not been 
analysed in previous studies. Furthermore, lifetime antibiotic use was 
associated with increased BMI only among the children who received 
macrolide courses during their early life (III), indicating that early-life 
microbiota composition affects the child’s later susceptibility to antibiotic-
associated weight gain. Macrolide use itself was associated with changes in 
the microbiome (III) that have been linked with increased BMI, adiposity, 
obesity or metabolic diseases in children or adults: low richness (Le Chatelier 
et al. 2013), reduction of bacterial bile-salt metabolism (Joyce et al. 2014), 
and reduction in bifidobacteria (Kalliomäki et al. 2008, Bergström et al. 
2014, Dogra et al. 2015a), increase in Bacteroides (Scheepers et al. 2015, 
Haro et al. 2016), increase in Erysipelotrichaceae (Zhang et al. 2009), and 
decrease in Christensenellaceae (Goodrich et al. 2014). Furthermore, mice 
treated with macrolides, but not those treated with amoxicillin (a penicillin-
type antibiotic), have an increased susceptibility in later life to excess fat 
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accumulation (Nobel et al. 2015). The microbiota changes associated with 
macrolide treatment may explain the obesogenic effect of early-life broad-
spectrum antibiotic courses (Bailey et al. 2014). These results, supported by 
earlier experiments with mice (Cho et al. 2012, Cox et al. 2014, Nobel et al. 
2015), suggest that the early-life microbiota composition is integrally involved 
in the long-term metabolic programming of infants.  
We therefore investigated the association between early-life microbiota 
composition and BMI in later childhood. The associations between the 
intestinal microbiota composition at the age of 3 months and BMI outcome at 
the age of 5-6 years were investigated in two cohorts (V), and were found to 
differ between the groups with low and high lifetime antibiotic use (Fig 7). 
This suggests that weight development may be affected by different factors in 
children with low and high lifetime antibiotic use. Several genus-level groups 
in the phylum Bacteroidetes (Bacteroides, Prevotella, Alistipes, 
Parabacteroides) were positively associated with later BMI in the children 
with low lifetime antibiotic use, i.e. were presumably predictive of 
susceptibility to diet-induced overweight. Strikingly, the same phylum was 
increased in a mouse model of early-life antibiotic exposure, causing 
increased sensitivity to diet-induced adiposity (Cox et al. 2014). In previous 
human studies, Bacteroides species, and particularly B. fragilis have been 
associated with increased BMI outcomes in later childhood, especially in 
children with low fibre intake (Vael et al. 2011, Scheepers et al. 2015). This 
indicates that a high abundance of Bacteroides in early life, caused by 
antibiotic use or other factors, may predispose to later diet-induced weight 
gain. 
Among the children with frequent lifetime antibiotic use, i.e. whose 
BMI both diet and the antibiotics likely affected, a low Actinobacteria-to-
Firmicute ratio at the age of 3 months predicted increased BMI at 6 years. 
The early microbiota composition thus appears predictive of later antibiotic-
associated weight gain. This supports the finding that macrolide use in early 
life, which we showed to practically eliminate Actinobacteria in children, is 
required for the later antibiotic-associated increase in BMI (III). Together 
these results and the finding that long duration of breastfeeding was 
associated with reduced BMI and increased Actinobacteria-to-Firmicute ratio 
at preschool age (II), indicate that early maturation of the microbiota, 
possibly due to early weaning or antibiotic use, may affect the child’s 
metabolic development.  
We cannot exclude the possibility that the associations between the early 
microbiota composition and later BMI development were caused by maternal 
effects, such as maternal diet influencing both the early microbiota and the 
BMI development. However, several lines of evidence support the idea that 
microbiota regulate metabolism and the development of the metabolic 
phenotype. In mice, antibiotic-induced weight gain, mediated by the 
microbiome, involves similar hormonal changes as diet-induced weight gain: 
increased levels of leptin and decreased levels of ghrelin and peptide YY (Cox 
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et al. 2014, Nobel et al. 2015). The common factor between an obesogenic diet 
and antibiotic use is that they both strongly alter the intestinal microbiota, 
which have the capacity to regulate the host’s energy homeostasis via e.g., 
FXR- and TGR5-signalling by bile acids (Watanabe et al. 2006, Joyce et al. 
2014), TLR4-signalling by lipopolysaccharide (LPS) (Song et al. 2006, Cani et 
al. 2007), Angptl4/Fiaf-signalling (Bäckhed et al. 2004, Camp et al. 2012), 
and gut hormone and adipose tissue regulation by SCFA production 
(Ichimura et al. 2009, Lin et al. 2012). There is thus ample evidence from 
animal studies supporting the notion that associations between breastfeeding, 
antibiotic use, early-life microbiota composition, and later BMI outcomes 
may be causal.  
 
 
 
Figure 7. Relative abundance of selected bacterial groups at the age of 3 months in children 
with low BMI (<15), intermediate BMI (15-16), and high BMI (>16) at the age of 5-6 years, 
with low or high (indicated by AB) lifetime antibiotic use (V). The bars show the group means 
and the whiskers show the standard errors. The average relative microbiota composition in 
the different groups is shown on the right. 
 
Increasing evidence is implying that bifidobacteria may have a key role in the 
metabolic programming of infants. Two Finnish studies based on one cohort 
have noted a negative, albeit not highly significant, association between 
abundance of Bifidobacterium spp. in infancy and later BMI development 
(Kalliomäki et al. 2008, Luoto et al. 2011). Furthermore, high abundance of 
Firmicutes and low abundance of bifidobacteria, suggestive of early 
microbiota maturation, has been associated with rapid growth and increased 
adiposity in infancy (Bergström et al. 2014, Dogra et al. 2015a). We found the 
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same associations among the children with frequent antibiotic courses. In 
mice, excessive abundance of clostridia in early life and rapid maturation of 
the microbiota has been achieved by antibiotic administration (Cho et al. 
2012, Cox et al. 2014). Human infants born via C-section and those weaned 
early have a more rapid maturation of the microbiota than vaginally born 
infants and those with long duration of breastfeeding (Bäckhed et al. 2015), 
which could contribute to the adipose phenotype associated with early 
weaning and C-section birth. Rapid development of the microbiome toward 
an adult-like composition in early infancy may enable fast growth in infants, 
which is known to predispose to overweight in later childhood (Stettler et al. 
2002, Baird et al. 2005). In addition, maternal overweight and stress during 
pregnancy, Caesarean delivery, antibiotic treatment during infancy and early 
weaning are all associated with increased risk of childhood overweight (Agras 
et al. 2004, Sloan et al. 2008, Li et al. 2010, Huh et al. 2012), and reduced 
abundance of bifidobacteria in the infant’s intestine (Penders et al. 2006, 
Collado et al. 2008, Collado et al. 2010, Santacruz et al. 2010, Bergström et 
al. 2014). Our results support the protective role of bifidobacteria against 
childhood overweight, especially against antibiotic-associated weight gain.  
The Gram-negative organisms, which we found increased in prenatally 
stressed infants (I), in children treated with antibiotics before weaning (II), in 
antibiotic-treated children (III, IV), in infants who later had high BMI 
outcomes (V), and in IBD-patients (VI), produce lipopolysaccharide (LPS), an 
inflammatory endotoxin. Circulating LPS induces inflammation, which affects 
glucose homeostasis and adipocyte metabolism (Geurts et al. 2014). 
Bacterially induced inflammation is considered an important component in 
the development of obesity and the related conditions, although the exact 
mechanisms are still unclear (Geurts et al. 2014). High-fat diets increase gut 
permeability and increase the amount of LPS leaking into circulation, thereby 
inducing low-grade inflammation (Geurts et al. 2014). Bifidobacteria reduce 
the leakage of LPS from the gut presumably by up-regulating tight-junction 
proteins and can thereby improve the metabolic health of the host and 
counter-act diet-induced weight gain (Cani et al. 2007, An et al. 2011, 
Neyrinck et al. 2012). In adult humans, obesity and related metabolic 
markers have been shown to correlate negatively with the abundance of 
bifidobacteria (Santacruz et al. 2010, Karlsson et al. 2012, Million et al. 
2012). It is thus possible that bifidobacteria have a role in the early 
development of the intestinal barrier in infants and protect against LPS-
induced systemic inflammation during a time when Gram-negative bacteria 
represent a considerably component of the microbiota. Frequent antibiotic 
use, increasing the abundance of Gram-negative bacteria and reducing the 
abundance of gut-protective bacteria, may involve recurrent LPS surges, 
similar to effects of a high-fat diet (Pendyala et al. 2012), which could 
contribute to the association between antibiotic use and weight gain.  
Overall, the results indicate that the healthy infant microbiome 
undergoes succession in an orderly manner. Both delayed and too rapid 
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succession may be detrimental to the infant’s metabolic and immunological 
development. Bifidobacteria may thus be seen as an indicator group, a 
biomarker of current and future health in infants. The results suggest that the 
early-life microbiota are involved in long-lasting metabolic programming, and 
can be used a biomarker of later obesity risk. The identification of infants with 
an obesogenic microbiota and tailored bacteriotherapy may thus represent a 
novel avenue in the battle against childhood overweight. 
From an evolutionary perspective, the effect of early microbiota on the 
metabolic phenotype may be caused by adaptive phenotypic plasticity 
(Bateson et al. 2004). The microbiota may act as a signal to the infant of 
prevailing food availability and therefore adaptively guide the development of 
the metabolic phenotype. A diet low in breast milk in infancy would indicate 
prevailing food scarcity, as poor maternal nutritional condition limits her 
ability to produce breast milk (Rasmussen 1992). This would be reflected in 
the microbiota as a low abundance of HMO-utilising bacteria and a high 
abundance of Firmicutes. The adaptive response would be the development of 
an energy-conserving metabolic phenotype. However, in the modern world, 
breastfeeding and prevailing food availability are not coupled, potentially 
creating a mismatch between infant phenotype and the environment. 
Antibiotic use also disrupts the link between early-life nutrition and 
microbiota composition, by reducing the abundance of bifidobacteria even if 
the infant is breastfed (Tanaka et al. 2009). If the infant is metabolically 
prepared for scarcity but receives ample nutrition, the result is likely to be fast 
growth in early life and increased susceptibility to metabolic diseases.  
Responses to Anti-TNF-α  therapy in IBD depend on the 
microbiota (VI) 
 
In paediatric IBD patients, we found that the microbiota varied along a 
gradient of intestinal inflammation. Higher levels of inflammation, measured 
by calprotectin, were associated with reduced microbial richness, reduced 
relative abundance of butyrate producers, and increased relative abundance 
of Gram-negative bacteria. Some IBD patients had a microbiota similar to 
healthy controls, while others had a dramatically increased abundance of 
Gram-negative organisms, either enterobacteria or Bacteroides spp, 
demonstrating that the microbiota of IBD patients can take different forms. 
The response to anti-TNF-α treatment was associated with the microbiota 
composition at baseline; high microbiota similarity to healthy controls 
predicted positive response to anti-TNF-α treatment (Fig 8). Among the most 
predictive organisms were Bifidobacterium and relatives of the butyrate-
producing species Eubacterium rectale, whose high abundance predicted 
positive treatment outcome. The treatment response was also correlated with 
the microbiota response: an increase in diversity and similarity to healthy 
controls was accompanied by a decrease in inflammation. These results 
suggest that patients with a normal-like microbiota are likely to benefit from 
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the blockage of TNF-α. It is possible that in this subgroup of patients, IBD is 
primarily a result of an excessive immune reaction towards the normal 
microbiota, and dampening the immune reaction is sufficient to achieve a 
positive treatment outcome. Patients with a severely distorted microbiota 
may require microbiota modulation in addition to immune modulation to 
achieve positive treatment outcomes. An interesting option is faecal 
transplantation, which can be used to reset the microbiota to a new ecological 
state (Smits et al. 2013). However, the donor should be selected carefully to 
ensure that the source microbiota contain a large amount of taxa that are 
depleted in the patient and a minimal amount of IBD-associated taxa. 
 
 
Figure 8. Average relative microbiota composition in healthy controls (CTRL) and baseline 
composition in IBD-patients who responded to anti-TNF-α therapy and IBD-patients who 
did not respond.  
 
While the aetiology of IBD is unknown, antibiotic use during childhood is an 
identified risk factor (Virta et al. 2012). Two healthy controls in study VI, who 
had used antibiotics prior to sample donation, had microbiota compositions 
similar to the IBD cases. Correspondingly, one of the subjects in studies III 
and IV, with a history of repeated macrolide courses, was diagnosed with UC 
during the follow-up. In studies III and IV, we observed that antibiotics, and 
macrolides particularly, drive the microbiota towards an IBD-like 
composition characterized by low diversity and a high abundance of Gram-
negative bacteria. It is an intriguing hypothesis that repeated antibiotic 
disturbances causing alterations in the microbiota might cause the immune 
system in genetically susceptible individuals to become increasingly hostile 
towards the altered microbiota, igniting an inflammatory response, which 
eventually prevents recovery and exacerbates the dysbiosis. Species related to 
B. fragilis and B. ovatus, the two groups that were strongly increased in the 
macrolide-users (III) and patients with Crohn’s disease (VI), have been 
associated with aberrant immune function, including increased IgE levels and 
autoimmunity (Saitoh et al. 2002, Sepp et al. 2005, de Goffau et al. 2013, 
Murri et al. 2013, de Goffau et al. 2014), and with intestinal symptoms (San 
Joaquin et al. 1995, Manichanh et al. 2014). These results link the observed 
associations between antibiotic use, microbiota composition, and IBD. 
 
NonResponderResponderCTRL
Actinobacteria
Clostridia
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How to encourage the natural microbiota development  
 
The results indicate that to encourage a healthy infant microbiota 
development, maternal wellbeing during pregnancy is a key factor. Maternal 
stress, either directly or due to factors such as diet, metabolic health, or 
inflammation, may affect her microbiota composition and the transmission of 
bacteria to the infant. Early-life exposures, perhaps most prominently the 
duration of breastfeeding and antibiotic use, appear to have long-term 
consequences on the development of the child and the microbiota, confirming 
that breastfeeding for at least 12 months should be encouraged, and antibiotic 
use during infancy restricted to necessary cases. In general, antibiotic 
treatment of infants and children should be conducted with caution and the 
choice of antibiotic considered carefully. Penicillin should be the first choice 
whenever possible. The pharmacokinetics of the antibiotic may be a useful 
indicator of the potential collateral damage caused by the drug in the 
intestine. Specific probiotics may be helpful in reducing the antibiotic-
induced damage in the intestinal microbiota of children, but attention should 
be paid to match the antibiotic with the right probiotic. LGG may help prevent 
or reduce the effects of penicillin-type antibiotics, but not those of macrolides. 
Hypothetically, Bifidobacterium supplementation may be helpful in 
ameliorating the effects of macrolides, although this should be investigated.  
 
Limitations of the studies 
 
Microbiota was analysed by DNA-based methods from faecal samples, which 
is currently the standard way to assess the intestinal microbiota. Many factors 
are known to potentially influence the reliability of the observed microbial 
composition (Thomas et al. 2015). The faecal microbiota is known to differ 
from the colonic luminal microbiota and even more from the colonic mucosal 
microbiota (Zoetendal et al. 2002, Eckburg et al. 2005). The mucosal 
microbiota are in close interaction with the host and may therefore be more 
important for the health of the host. However, the collection of mucosal 
biopsies is invasive and not possible in most cases. The use of faecal samples 
should not seriously confound the results, as the microbiota was consistently 
analysed from faecal samples in all cases; inter-individual comparisons are 
likely to be reliable although the absolute quantities of bacterial taxa in the 
intestine, and particularly in the mucosa, cannot be ascertained. Indeed, the 
results are based on relative abundances of bacterial taxa; measuring absolute 
abundances from faecal samples is complicated but could provide additional 
insights. 
Timing of the faecal sample collection (Thaiss et al. 2014) and stool 
consistency (Vandeputte et al. 2016) are known to affect the microbiota 
composition. Neither was controlled in these studies. These are not likely to 
consistently vary between the different groups and therefore should not 
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seriously confound the results. Sample storage, DNA extraction method, and 
analysis platform including the primers used are also known to influence the 
observed composition (Thomas et al. 2015). In all studies the samples were 
collected at home and taken immediately to the study centre for storage in     -
70°C, or stored temporarily in the home freezer for a few hours. This protocol 
should cause minimal taxonomic bias, and ensure comparability between 
samples.  
Different DNA extraction methods are known to be biased in their 
ability to retrieve DNA from different types of bacteria (Salonen et al. 2010, 
Thomas et al. 2015). Mechanical lysis using repeated bead beating is currently 
considered the best method to extracting DNA (Salonen et al. 2010, Santiago 
et al. 2014). This method was used for the infant samples. The samples from 
the 2-7 year old children were subjected to a modified protocol using the 
Promega Wizard kit, which has been shown to produce very similar results to 
the RBB method (Salonen et al. 2010). The platform used for quantifying the 
different taxonomic groups based on the DNA may exert additional biases. 
Two platforms targeting 16S rRNA amplicons, a microarray and 
pyrosequencing, were used, and their results compared. Both platforms 
provided corresponding results (III, IV) indicating that the results are not 
platform-specific: for example, the relative abundance of Bifidobacterium 
measured using the two platforms showed a between-platform correlation of 
0.88. 
The predictor variables, such as prenatal stress (I), duration of 
breastfeeding (II), antibiotic use (III), probiotic use (IV), and BMI (II, III, V) 
are likely to contain some amount of error. Prenatal stress was measured by 
validated questionnaires and measurements of cortisol, so the accuracy is 
likely to be fairly high: mothers with high scores on both experienced stress 
and measured cortisol most likely did experience more stress than those with 
low scores on both variables. Information on the duration of breastfeeding 
was obtained from the mothers up to 6 years after the child was born. It is 
possible that some mothers remembered the exact duration better than 
others, and recall bias cannot be ruled out as an alternative explanation to 
some of the results. If the mothers of antibiotic-using infants consistently 
recalled the duration of breastfeeding less accurately than the mothers of 
healthy infants, the apparent lack of association between breastfeeding 
duration and BMI could be explained by recall bias. 
The drug purchase records are highly accurate and known to contain 
>95% of all drug purchases.  However, a few antibiotic purchases were 
inevitably missed: drugs given during hospital stays would not be recorded 
nor would drugs purchased without showing the social insurance card. We 
compared the parent-reported number of antibiotic courses to the purchase 
records and found considerable differences. Even the antibiotic prescription 
data from the study physicians, which the families were advised to visit, did 
not fully match the purchase data, indicating that not all prescriptions were 
filled and that additional prescriptions were obtained from other physicians. 
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The antibiotic purchase data can be considered the most reliable and 
objective indicator of antibiotic use. 
The probiotic intervention was well controlled. Most of the study milk 
was given to the children at the day care facility by the staff, which also 
monitored milk consumption. Compliance was further confirmed by 
analysing the amount of the probiotic strain in the faecal samples. Discordant 
samples were excluded. The BMI data for papers II, III and V were based on 
weight and height data measured by researchers or physicians and are 
therefore consistently measured and reliable. 
 
Generality of the results 
 
The results are based on four cohorts of children from two different countries, 
and they can be expected to generalize well to other, similar child cohorts. 
Similar or supportive findings have been discovered in animal studies, and in 
different cohorts of children and adults. However, all studies included in this 
work were restricted to healthy infants and children (with the exception of the 
IBD cases) in two European countries, and extrapolation to dissimilar cohorts 
may not be possible. 
 The prenatal stress study (I) excluded families with pregnancy 
complications, C-section birth, and serious infant health problems. Therefore, 
the results may only apply to vaginally born healthy infants. Antibiotic use 
was extremely rare during the study, and the results may not apply to infants 
taking antibiotics. The inter-individual microbiota variation among the Dutch 
infants was smaller than among the Finnish infants (V), suggesting that the 
results based only on the Dutch cohort may generalise only to a subset of 
infants. However, animal studies have shown very similar results (Bailey et al. 
2004), indicating that the results on the effect of maternal stress on the gut 
microbiota generalise even across species borders. 
 The effect of breastfeeding duration on BMI, lifetime antibiotic use, 
and the later-life microbiota composition (II), as well as the associations 
between antibiotic and probiotic use and the microbiota composition (III, IV) 
were based on a fairly homogenous and healthy Finnish cohort, all attending 
day care. Children of other ethnicities or living in different environments may 
not show the same results. However, the association between early-life 
antibiotic use and later-life BMI has been found in a number of studies in 
different countries (Ajslev et al. 2011, Trasande et al. 2013, Azad et al. 2014, 
Bailey et al. 2014, Saari et al. 2015, Gerber et al. 2016), suggesting good 
generality. The association between duration of breastfeeding and BMI has 
also been observed in different cohorts (Arenz et al. 2004, Harder et al. 
2005), although results to the contrary exist as well (Owen et al. 2005). To 
what extent the controversy is explained by antibiotic use, should be 
investigated in larger cohorts. The association between breastfeeding 
duration and microbiota composition (II) was based on a subset of only 42 
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non-overweight, non-asthmatic children with modest lifetime antibiotic use. 
In the total cohort the same patterns emerged, but were dampened by 
variations in antibiotic use, BMI, and health. The results thus may not fully 
apply to overweight or asthmatic children, or children with heavy antibiotic 
use history. 
 The associations between early-life microbiota composition and later-
life BMI were based on children from two different countries with different 
childcare practices. The results are furthermore supported by previous studies 
on Finnish (Kalliomäki et al. 2008, Luoto et al. 2011) and Dutch children 
(Vael et al. 2011, Scheepers et al. 2015), suggesting that the results should 
generalise well at least among European children. 
 
Causality not concluded 
 
Data for papers I and V were collected as part of an observational study on 
child development and data for papers II-V were collected during probiotic 
trials. Apart from paper IV, in which the outcome of the probiotic trial was 
analysed, all papers present observational data. The observed correlations 
should not be taken as evidence of causality, nor can they reveal the causal 
mechanisms underlying the relationships. However, the results are supported 
by previous animal experiments and epidemiological studies, which provide 
ample support to the results presented here and evidence of causality. 
Furthermore, analysing bacterial bile-salt hydrolase and antibiotic resistance 
genes in paper III identified links to potential mechanisms. Antibiotic 
resistance showed a clear causal signal in the antibiotic treated children, 
which supports causality of the overall antibiotic-associated microbiota 
changes.  
Future considerations 
 
Further research in tightly controlled cohorts with detailed metadata and host 
parameters, including markers of immunological function, inflammation, and 
metabolism will be helpful to establish causality and to delineate the 
mechanisms underlying the observed associations. Humans and their 
microbiomes are known to exhibit a considerable amount of individuality due 
to differences in environment, genetics, and experiences. Therefore, assuming 
uniform responses in microbiome studies is inevitably too simplistic and 
likely to result in the missing of important signals in the data. Large cohorts 
with detailed metadata enable the accommodation of individuality in the 
microbiota and host responses by meaningful stratification of individuals into 
biologically comparable groups.  
As bacterial bile acid metabolism and LPS-induced inflammation are 
implicated in the metabolic regulation of the host, measurements of bile acids 
in faeces and in blood, and markers of immune activation and inflammation 
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in blood should be undertaken in future studies, in conjuction with 
compositional and functional analyses of the microbiome. Whole-genome 
metagenomics and metaproteomics can reveal functions of the bacteria, but 
are still too expensive for most large-scale studies. The work presented here 
mainly consisted of compositional analyses, but some functional aspects were 
included, as well. The results show that fairly simple culture-based and PCR-
based analyses can provide important complementary information to the 
high-throughput microarray or sequencing analyses. Whole-genome 
metagenomics was successfully used as a discovery tool to guide further 
analyses. 
Although it is becoming evident that the early-life microbiome exerts 
long-term impacts on host health, it is still not clear which age is the most 
decisive for host development. A recent study found that antibiotic use during 
the first 6 months of life was less predictive of later weight gain than 
antibiotic use during the first 2 years of life (Gerber et al. 2016). We found 
that macrolide use during the first 2 years was most predictive of later 
antibiotic-associated weight gain and of asthma incidence. These results 
suggest that the sensitive time window is at least 2 years, if not longer, and 
that it may be necessary to look beyond the first few months. 
Most importantly, in order to progress from pattern description to 
prediction-level understading of the dynamics and functions of the 
microbiome, long time series are essential. In macro-ecology, population 
monitoring through time series is considered the cornerstone of 
understanding ecosystem dynamics and functioning. Long time series 
collected at short intervals from well characterised individuals with 
simultaneous recording of host exposures, such as diet, living environment, 
medical treatments, and host health parameters will be a step towards 
estabilishing causality between host exposures and microbiota changes, and 
between microbiota changes and host parameters. Rather than analysing the 
relative abundance of bacterial taxa at given time points, the time series 
approach will enable the analysis of change in relative abundance, and 
consequently the predition of change, within the context of the individual 
composition.  
Summary and Conclusions 
 
The results show that the intestinal microbiota composition in early life 
predicts weight development in later childhood, and suggest that disruption 
of the natural microbiota development may have long-term health 
consequences. The microbiota in childhood appear sensitive to various 
modulating factors. Environmental factors begin to influence the microbiota 
even before birth, and therefore promoting maternal heath and wellbeing is 
the first step towards healthy microbiota in the child. Long duration of 
breastfeeding was associated with the microbiota development, as well as 
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reduced antibiotic use and BMI in preschool age, but antibiotic use before 
weaning weakened these associations. The results support the health-
promoting effects of breastfeeding and indicate that some of the benefits of 
breastfeeding are microbiota-dependent. Antibiotic use during childhood 
emerged as a central regulator of the microbiome and its long-term 
development, with potential effects on the metabolic development of the 
child. Particularly macrolide use was associated with potentially obesogenic 
changes in the microbiome. Antibiotic use in early life, and particularly the 
use of macrolides, should be avoided if possible. Probiotic use during and 
after antibiotic courses may offer a way to mitigate some of the antibiotic-
associated changes, but the probiotic should be matched with the antibiotic. 
LGG supplementation prevented some of the penicillin-associated changes, 
but failed to prevent the macrolide-associated loss of bifidobacteria. 
Supplementation with bifidobacteria may be beneficial in association with 
macrolide courses.  
  Based on the results, the following model emerges (Fig. 9). Long 
breastfeeding is associated with reduced risk of overweight, but the benefit is 
eliminated by antibiotic use in infancy. Long duration of breastfeeding, and 
LGG supplementation, protect against infections and thus prevent antibiotic 
use. Prenatal stress and antibiotic use in childhood alter the microbiota 
development, and the altered microbiota composition in infancy is associated 
with later weight development. Generally, this work suggests that promoting 
a natural microbiota development in childhood by breastfeeding, avoiding 
unnecessary antibiotics, and possibly probiotic use, may have long-term 
health benefits, particularly in terms of weight development. 
 
 
Figure 9. A tentative model based on the associations found in this thesis project. LGG = 
Lactobacillus rhamnosus GG supplementation. Red = preventing association, green = 
promoting association. 
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